Neo Ivy Capital Management purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 48,584 shares of the biotechnology company's stock, valued at approximately $972,000.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the last quarter. Assenagon Asset Management S.A. grew its position in ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after buying an additional 92,281 shares during the last quarter. Citigroup Inc. increased its stake in ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares during the period. Seven Eight Capital LP purchased a new position in ADMA Biologics during the 2nd quarter worth $1,992,000. Finally, Principal Financial Group Inc. raised its position in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after buying an additional 1,059,394 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th.
Get Our Latest Report on ADMA Biologics
ADMA Biologics Price Performance
ADMA traded down $0.96 on Thursday, hitting $18.67. 2,134,739 shares of the company were exchanged, compared to its average volume of 3,590,190. ADMA Biologics, Inc. has a fifty-two week low of $3.73 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market capitalization of $4.41 billion, a P/E ratio of 66.68 and a beta of 0.70. The business's fifty day moving average is $19.05 and its 200 day moving average is $15.94.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the firm posted $0.01 EPS. As a group, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current year.
Insider Activity
In related news, CFO Brad L. Tade sold 15,000 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 3.70% of the company's stock.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
